Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology
https://doi.org/10.4081/aiua.2022.3.291
Accepted: August 20, 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Purpose: The aim of this study is to report our experience in managing bladder cancer in patients with variant pathology.
Methods: Retrospective data collection for all patients managed by radical cystectomy over the last 3 years for a variant pathol-ogy was completed. We specifically included micropapillary and nested variants.
Results: Ten patients were identified, with eight having micropapillary carcinoma (MPC) and two having nested vari-ants. Nine patients were male. The median age was 75. The two patients with nested variant were 56 and 62 years old, respec-tively, whereas all patients with MPC were over the age of 70. Upon cystectomy of all micropapillary cases, three patients
(37.5%) had positive lymph node invasion and the final patholo-gy was T2 (two patients), T3 (two patients), and T4 (four patients). Barring a grade III complication Clavien-Dindo classi-fication due to wound dehiscence that necessitated secondary surgical closure, there were no specific perioperative complica-tions. Given the urethral invasion, cystourethrectomy was per-formed on the female patient. Within a median 13-month fol-low-up, three patients developed local recurrence, including two urethral and one new lateral pelvic mass.
Conclusions: Considering the muscle invasive nature of micropapillary and nested bladder cancer, aggressive surgical management should not be postponed. Moreover, due to notable prevalence of concurrent and/or recurrent urethral involvement, initial urethrectomy or early and frequent postoperative ure-throscopy should be provided. Patients with variant histology bladder cancer may benefit from early radical cystectomy when compared to bladder sparing protocols and prostate sparing cystectomy treatment options.
Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009; 3(6 Suppl 4):193-198. DOI: https://doi.org/10.5489/cuaj.1195
Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016; 70:106-119. DOI: https://doi.org/10.1016/j.eururo.2016.02.028
Burger M, Kamat AM, McConkey D. Does variant histology change management of non-muscle-invasive bladder cancer? Eur Urol Oncol. 2021; 4:510-514. DOI: https://doi.org/10.1016/j.euo.2019.06.012
Shapur NK, Katz R, Pode D, et al. Is radical cystectomy manda-tory in every patient with variant histology of bladder cancer. Rare Tumors. 2011; 3:e22. DOI: https://doi.org/10.4081/rt.2011.e22
Barata PC, Rini BI. Treatment of renal cell carcinoma: Current sta-tus and future directions. CA Cancer J Clin. 2017; 67:507-524. DOI: https://doi.org/10.3322/caac.21411
Sefik E, Celik S, Basmaci I, et al. Effect of variant histology pres-ence and squamous differentiation on oncological results and patient's survival after radical cystectomy. Arch Ital Urol Androl. 2018; 90:172-175. DOI: https://doi.org/10.4081/aiua.2018.3.172
Pereira JN, Reis JD, Braga I, et al. Variant histologies of urothelial carcinoma: Does it change the survival outcomes in patients managed with radical cystectomy? Arch Ital Urol Androl. 2022; 94:138-143. DOI: https://doi.org/10.4081/aiua.2022.2.138
Black AJ, Black PC. Variant histology in bladder cancer: diagnos-tic and clinical implications. Transl Cancer Res. 2020; 9:6565-6575. DOI: https://doi.org/10.21037/tcr-20-2169
Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive blad-der cancer with variant histology. Cancer. 2017; 123:4346-4355. DOI: https://doi.org/10.1002/cncr.30907
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sen-sitivities to frontline chemotherapy. Cancer Cell. 2014; 25:152-165. DOI: https://doi.org/10.1016/j.ccr.2014.01.009
Horwich A, Babjuk M, Bellmunt J, et al. EAU–ESMO consensus statements on the management of advanced and variant bladder can-cer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Ann Oncol. 2019; 30:1697-1727. DOI: https://doi.org/10.1093/annonc/mdz296
Compérat E, Roupret M, Yaxley J, et al. Micropapillary urothe-lial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010; 42:650-654. DOI: https://doi.org/10.3109/00313025.2010.522173
Ramos P, Pereira P, Dinis P, Pacheco-Figueiredo L. Bladder can-cer variant histologies: epidemiology, diagnosis, treatment and prog-nosis. In Ed F. Ziglioli Modern approach to diagnosis and treatment of bladder cancer. IntechOpen 2021. DOI: https://doi.org/10.5772/intechopen.98246
Berg S, D’Andrea D, Vetterlein MW, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019; 125:1449-1458. DOI: https://doi.org/10.1002/cncr.31952
Lobo N, Shariat SF, Guo CC, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020; 6:653-663. DOI: https://doi.org/10.1016/j.euf.2019.09.003
Sui W, Matulay JT, James MB, et al. Micropapillary bladder can-cer: insights from the National Cancer Database. Bladder Cancer. 2016; 2:415-423. DOI: https://doi.org/10.3233/BLC-160066
Black PC, Brown GA, Dinney CPN. The impact of variant his-tology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009; 27:3-7. DOI: https://doi.org/10.1016/j.urolonc.2007.07.010
Chua KLM, Kusumawidjaja G, Murgic J, Chua MLK. Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?ESMO open. 2016; 1:e000123. DOI: https://doi.org/10.1136/esmoopen-2016-000123
Honma I, Masumori N, Sato E, et al. Local recurrence after rad-ical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology. 2004; 64:744-748. DOI: https://doi.org/10.1016/j.urology.2004.05.003
Zaghloul MS, Awwad HK, Akoush HH, et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992; 23:511-517. DOI: https://doi.org/10.1016/0360-3016(92)90005-3
Lewis GD, Haque W, Verma V, et al. The role of adjuvant radia-tion therapy in locally advanced bladder cancer. Bladder Cancer. 2018; 4:205-213. DOI: https://doi.org/10.3233/BLC-180163
Willis DL, Fernandez MI, Dickstein RJ, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015; 193:1129-1134. DOI: https://doi.org/10.1016/j.juro.2014.09.092
Venyo AK. Nested variant of urothelial carcinoma. Adv Urol. 2014; 2014:192720. DOI: https://doi.org/10.1155/2014/192720
Warrick JI. Clinical significance of histologic variants of bladder cancer. J Natl Compr Canc Netw. 2017; 15:1268-1274. DOI: https://doi.org/10.6004/jnccn.2017.7027
Aron M. Variant histology in bladder cancer-current understand-ing of pathologic subtypes. Curr Urol Rep. 2019; 20:80. DOI: https://doi.org/10.1007/s11934-019-0949-6
Lopez-Beltran A, Henriques V, Montironi R, et al. Variants and new entities of bladder cancer. Histopathology. 2019; 74:77-96. DOI: https://doi.org/10.1111/his.13752
Beltran AL, Cheng L, Montironi R, et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary blad-der. Virchows Arch. 2014; 465:199-205. DOI: https://doi.org/10.1007/s00428-014-1601-y
Linder BJ, Frank I, Cheville JC, et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013; 189:1670-1675. DOI: https://doi.org/10.1016/j.juro.2012.11.006
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
